stockportfolio.pro
Damora Therapeutics, Inc. (DMRA)
Healthcare · Biotechnology · NasdaqCM
Damora Therapeutics, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-36.51M | $-34.84M | $-51.75M | $-61.62M | $-38.35M | $-21.44M | $-209.84M |
| Net margin | — | — | — | — | — | — | — |
Source: Damora Therapeutics, Inc. SEC filings (10-K).
Explore 7 years of Damora Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DMRA in your portfolio →
Damora Therapeutics, Inc. financial history by metric
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. — frequently asked questions
What is Damora Therapeutics, Inc.'s revenue?
Damora Therapeutics, Inc. (DMRA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Damora Therapeutics, Inc. profitable?
No — DMRA reported a net loss of $-209.84M in fiscal 2025.
What is DMRA's P/E ratio?
Damora Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Damora Therapeutics, Inc. have?
As of fiscal year 2025, DMRA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Damora Therapeutics, Inc.'s market cap?
Damora Therapeutics, Inc. (DMRA) has a market capitalization of about $1.29B, based on the latest data in our nightly-refreshed cache.
When does Damora Therapeutics, Inc.'s fiscal year end?
DMRA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Damora Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.